Last Updated: November 16, 2026

Investigational Drug Information for PF-07081532

« Back to Dashboard


What is the development status for investigational drug PF-07081532?

PF-07081532 is an investigational drug.

There have been 11 clinical trials for PF-07081532. The most recent clinical trial was a Phase 1 trial, which was initiated on November 8th 2022.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Overweight. The leading clinical trial sponsors are Pfizer and [disabled in preview].

There are sixteen US patents protecting this investigational drug and twenty-seven international patents.

Recent Clinical Trials for PF-07081532
TitleSponsorPhase
A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult ParticipantsPfizerPhase 1
A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese AdultsPfizerPhase 1
A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or ObesePfizerPhase 1

See all PF-07081532 clinical trials

Clinical Trial Summary for PF-07081532

Top disease conditions for PF-07081532
Top clinical trial sponsors for PF-07081532

See all PF-07081532 clinical trials

US Patents for PF-07081532

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PF-07081532 ⤷  Start Trial GLP-1 receptor agonists and uses thereof Pfizer Inc. (New York, NY) ⤷  Start Trial
PF-07081532 ⤷  Start Trial GLP-1 receptor agonists and uses thereof Pfizer Inc. (New York, NY) ⤷  Start Trial
PF-07081532 ⤷  Start Trial GLP-1 receptor agonists and uses thereof Pfizer Corp SRL ⤷  Start Trial
PF-07081532 ⤷  Start Trial BCKDK inhibitors Pfizer Corp SRL ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PF-07081532

Drugname Country Document Number Estimated Expiration Related US Patent
PF-07081532 Argentina AR114967 2038-06-13 ⤷  Start Trial
PF-07081532 Australia AU2019285491 2038-06-13 ⤷  Start Trial
PF-07081532 Brazil BR112020024470 2038-06-13 ⤷  Start Trial
PF-07081532 Canada CA3045644 2038-06-13 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

PF-07081532 Development Update and Market Projection

Last updated: October 11, 2026

PF-07081532, also known as lotiglipron, was Pfizer’s oral small-molecule GLP-1 receptor agonist for type 2 diabetes and obesity. Pfizer discontinued the program in 2023 after a clinical study identified liver-enzyme elevations. The asset has no active development path, no FDA approval, no Orange Book listing, and no credible standalone commercial revenue forecast. Its market value is effectively zero unless Pfizer or a third party revives the molecule after new safety and dose-selection work.

What is PF-07081532?

PF-07081532 was an orally administered, non-peptide GLP-1 receptor agonist discovered and developed by Pfizer. It was designed to activate the GLP-1 receptor without the injection requirements associated with injectable semaglutide, tirzepatide, and related products.

Attribute PF-07081532
Generic name Lotiglipron
Developer Pfizer
Molecular class Oral small-molecule GLP-1 receptor agonist
Primary targets Type 2 diabetes and obesity
Route Oral
Development status Discontinued
FDA approval None
FDA regulatory exclusivity None
Orange Book listing None
Commercial sales None
Key development issue Liver-enzyme elevations
Principal competitive products Wegovy, Ozempic, Rybelsus, Mounjaro, Zepbound

PF-07081532 was distinct from Pfizer’s other oral GLP-1 candidate, danuglipron, also known as PF-06882961. Pfizer continued to evaluate danuglipron after stopping lotiglipron, although danuglipron also faced development and tolerability challenges.

Why did Pfizer discontinue PF-07081532?

Pfizer stopped PF-07081532 development after a Phase 2 study in people with type 2 diabetes showed elevations in alanine aminotransferase and aspartate aminotransferase, commonly referred to as ALT and AST.

The company disclosed the decision in June 2023. Pfizer stated that the liver-enzyme findings were observed without evidence of liver dysfunction, but the overall safety profile did not support continuing the program. The decision was a clinical-development termination rather than a regulatory rejection.

Development timeline

Date Event
2021-2022 PF-07081532 entered early clinical development as an oral GLP-1 receptor agonist
2022 Pfizer evaluated the candidate in Phase 1 and Phase 2 studies involving diabetes and obesity-related endpoints
June 2023 Pfizer discontinued PF-07081532 after liver-enzyme elevations in a Phase 2 study
2023 onward Pfizer redirected oral GLP-1 investment toward danuglipron and other metabolic programs
Current status No active public clinical-development program for lotiglipron

Pfizer’s decision was commercially significant because the asset was intended to compete in a rapidly expanding obesity market where an effective oral GLP-1 product could command substantial demand. The safety signal removed Pfizer’s most advanced second oral small-molecule GLP-1 program from that competitive field.

What clinical data were reported for PF-07081532?

Public disclosures indicated that PF-07081532 produced pharmacologic activity consistent with GLP-1 receptor agonism, including effects on glucose control and body weight. The available public record did not establish a clinically competitive benefit-risk profile sufficient to support Phase 3 development.

The program’s principal limitation was safety rather than a demonstrated lack of GLP-1 efficacy. Pfizer did not disclose a comprehensive late-stage efficacy package before termination, and no pivotal registration study was initiated.

Publicly reported clinical characteristics

  • Oral, once-daily administration was part of the development concept.
  • The candidate was evaluated in patients with type 2 diabetes.
  • Weight reduction was assessed as an obesity-related development objective.
  • Liver-enzyme elevations emerged during clinical testing.
  • Pfizer did not advance the candidate into confirmatory Phase 3 trials.
  • No long-term cardiovascular outcomes program was initiated.

The absence of Phase 3 data prevents a reliable comparison with the approved efficacy profiles of semaglutide and tirzepatide.

What is the FDA status of PF-07081532?

PF-07081532 has no FDA approval, no New Drug Application approval, and no FDA-recognized commercial exclusivity.

FDA and regulatory status

Regulatory issue Status
Investigational status Clinical-stage asset only
Approved indication None
NDA approval None
FDA label None
REMS None
New chemical entity exclusivity None
Orphan-drug exclusivity None
Pediatric exclusivity None
Orange Book listing None
ANDA litigation pathway Not applicable

The candidate therefore has no approved-label protection and no practical regulatory barrier to development by another sponsor, subject to patent rights, clinical data rights, and manufacturing considerations.

What patents protect PF-07081532?

Publicly available information does not establish an active, commercially meaningful patent estate that could support a launch forecast for lotiglipron after the clinical program’s termination.

Pfizer likely filed patent applications covering one or more of the following:

  • The PF-07081532 chemical entity
  • Markush compounds and related GLP-1 receptor agonists
  • Pharmaceutical compositions
  • Oral dosage forms
  • Methods of treating diabetes
  • Methods of reducing body weight
  • Manufacturing processes and intermediates

Patent-family identification requires a verified search of USPTO, WIPO, EPO, and national registers using the compound code, lotiglipron, chemical structure, and Pfizer assignee records. The public development record alone does not establish which applications matured into granted patents, which claims remain enforceable, or whether any family covers the clinical compound specifically.

Patent-life assessment

Patent category Public commercial impact
Compound patents Potentially relevant, but no verified enforceable claim set established here
Formulation patents No approved formulation exists
Method-of-use patents No approved indication exists
Manufacturing patents Could restrict production, but no public launch program exists
Orange Book patents None
Patent litigation No material public Paragraph IV dispute identified
Settlement agreements None publicly associated with lotiglipron

Because PF-07081532 never reached approval, patent expiration dates do not create a conventional generic-entry timeline. Any future revival would depend on the remaining patent term, patent prosecution outcomes, freedom-to-operate analysis, and the sponsor’s ability to resolve the liver-safety issue.

Were there Paragraph IV challenges or patent litigation?

No material Paragraph IV litigation or generic patent challenge is publicly associated with PF-07081532.

Paragraph IV litigation normally follows an approved small-molecule product and Orange Book-listed patents. PF-07081532 did not reach that stage. A future developer would more likely face ordinary patent-validity, infringement, and freedom-to-operate issues than an ANDA-based challenge to an approved reference product.

No public settlement agreement between Pfizer and a generic manufacturer has been associated with lotiglipron.

How does PF-07081532 compare with danuglipron?

Danuglipron was Pfizer’s principal remaining oral small-molecule GLP-1 program after the termination of lotiglipron. The two candidates should not be treated as the same asset.

Factor PF-07081532, lotiglipron PF-06882961, danuglipron
Developer Pfizer Pfizer
Modality Oral small molecule Oral small molecule
Receptor target GLP-1 receptor GLP-1 receptor
Development status Discontinued Continued in development after lotiglipron termination
Key safety issue Liver-enzyme elevations Gastrointestinal tolerability and dosing challenges
Commercial status No approval No approval
Market opportunity No current opportunity absent revival Potential oral GLP-1 opportunity
Competitive position Removed from active pipeline Competing against oral semaglutide and future oral incretins

Pfizer announced in late 2023 that it discontinued a once-daily formulation of danuglipron after liver-enzyme elevations, while continuing to evaluate a twice-daily formulation. This later development increased the strategic importance of Pfizer’s oral metabolic portfolio but did not revive lotiglipron.

What is the market outlook for PF-07081532?

The direct market outlook is zero under the current discontinued status. PF-07081532 has no approval, no launch date, no reimbursed indication, and no projected revenue stream.

Its former target market remains attractive. Global demand for obesity and diabetes medicines is being driven by:

  • High prevalence of obesity and type 2 diabetes
  • Durable weight-loss effects from GLP-1 and GIP therapies
  • Expansion of treatment beyond diabetes
  • Limited injectable capacity
  • Patient demand for oral administration
  • Reimbursement expansion in selected markets
  • Use of chronic cardiometabolic therapies in earlier disease

The commercial opportunity is therefore tied to the mechanism and route, not to the discontinued lotiglipron asset.

Market comparison

Product Sponsor Route Status Commercial relevance
Wegovy, semaglutide Novo Nordisk Injectable Approved for obesity Major obesity product
Ozempic, semaglutide Novo Nordisk Injectable Approved for type 2 diabetes Major diabetes product
Rybelsus, semaglutide Novo Nordisk Oral Approved for type 2 diabetes Established oral GLP-1 benchmark
Mounjaro, tirzepatide Eli Lilly Injectable Approved for type 2 diabetes Major incretin product
Zepbound, tirzepatide Eli Lilly Injectable Approved for obesity Major obesity product
PF-07081532, lotiglipron Pfizer Oral Discontinued No current revenue
Danuglipron Pfizer Oral Development-stage Potential but unproven

Rybelsus establishes that an oral GLP-1 product can achieve commercial adoption. However, lotiglipron would have needed competitive weight loss, acceptable gastrointestinal tolerability, clean hepatic safety, convenient dosing, and reliable manufacturing to challenge semaglutide and tirzepatide.

What generic entry risks exist for PF-07081532?

There is no conventional generic-entry risk because no reference product exists. The relevant risk is asset revival risk.

A competitor seeking to develop lotiglipron or a structurally similar molecule could face:

  1. Pfizer composition-of-matter patent claims, if enforceable claims remain.
  2. Formulation or salt-form patents.
  3. Method-of-use patents for diabetes or obesity.
  4. Manufacturing-process patents.
  5. Clinical-development risk from the prior liver-enzyme signal.
  6. Regulatory requirements for repeat liver-safety monitoring.
  7. Competitive pressure from approved GLP-1 and GIP products.
  8. Pricing and reimbursement pressure in obesity treatment.

A generic manufacturer cannot file a standard ANDA for PF-07081532 because there is no approved reference drug. A future sponsor would need an independent development and regulatory strategy unless it acquired usable Pfizer data and rights.

Could PF-07081532 be revived or licensed?

A revival is possible in principle but commercially unlikely based on the available public record. Pfizer could license or sell the asset, but a transaction would require a convincing explanation of the hepatic signal and a viable clinical plan.

Potential transaction structures

  • Out-license to a company specializing in oral metabolic drugs
  • Asset sale with clinical-data transfer
  • Regional licensing after new toxicology review
  • Combination development with another metabolic agent
  • Reformulation or modified-release development
  • Repositioning for a narrower diabetes population

No public licensing deal has established a new owner or active development partner for lotiglipron.

A buyer would likely discount the asset heavily because it has no human proof-of-concept package suitable for registration, no approval, no commercial supply chain, and a known safety concern. The asset’s value would derive mainly from chemical know-how, patent rights, and historical clinical data.

What manufacturing and intellectual-property barriers apply?

Oral small-molecule GLP-1 programs face manufacturing barriers that differ from conventional generic tablets.

Potential technical constraints include:

  • Low or variable oral bioavailability
  • Food-effect sensitivity
  • Dose escalation requirements
  • High active pharmaceutical ingredient loading
  • Solid-state and polymorph control
  • Metabolite characterization
  • Exposure-related tolerability
  • Scale-up reproducibility
  • Stability and tablet dissolution
  • Drug-drug interaction assessment

PF-07081532’s development termination means Pfizer did not establish commercial-scale manufacturing for an approved product. Any future sponsor would need to reproduce the molecule, characterize impurities and metabolites, and establish a new clinical-quality manufacturing process.

What is the revenue exposure for Pfizer?

PF-07081532 did not generate product revenue. Its financial exposure was development investment and the loss of a potential position in the oral obesity market.

The opportunity cost was substantial because the obesity market expanded rapidly while Pfizer’s oral GLP-1 portfolio encountered setbacks. Pfizer’s remaining oral incretin strategy became concentrated around danuglipron and other pipeline assets rather than lotiglipron.

A direct revenue estimate for PF-07081532 is therefore:

Revenue category Projection
Current product sales $0
Near-term sales $0
Sales without program revival $0
Sales from a successful revival Not supportable from public data
Royalty revenue None publicly identified

Key Takeaways

  • PF-07081532, or lotiglipron, was an oral small-molecule GLP-1 receptor agonist developed by Pfizer.
  • Pfizer discontinued the program in 2023 after liver-enzyme elevations in a Phase 2 study.
  • The candidate has no FDA approval, Orange Book listing, regulatory exclusivity, or commercial revenue.
  • No material Paragraph IV challenge, patent litigation, or settlement agreement is publicly associated with the asset.
  • Patent rights may exist around the compound, formulations, uses, and manufacturing methods, but they do not create a conventional generic-entry timeline.
  • The former target market remains large, but the commercial opportunity belongs to active oral GLP-1 programs rather than lotiglipron.
  • Any revival would require a new safety strategy, adequate patent term, clinical investment, and a sponsor willing to compete against semaglutide and tirzepatide.

FAQs

Is PF-07081532 the same drug as danuglipron?

No. PF-07081532 is lotiglipron. Danuglipron is PF-06882961. Both are Pfizer oral small-molecule GLP-1 receptor agonists, but they are separate compounds.

Can patients obtain PF-07081532?

No. PF-07081532 is not an approved medicine and is not commercially available through ordinary prescribing channels.

Did PF-07081532 reach Phase 3?

No. Pfizer discontinued the program before pivotal Phase 3 development.

Does PF-07081532 have an estimated patent expiration date?

A reliable expiration date cannot be assigned from the public development record alone. The relevant date would depend on the specific compound patent family, filing date, patent term adjustment, patent term extension, and claim coverage.

Is PF-07081532 a potential generic competitor to Rybelsus?

No. PF-07081532 is a discontinued investigational compound, not a generic version of oral semaglutide. Any future development would require a separate regulatory pathway.

References

  1. Pfizer Inc. (2023). Pfizer provides update on clinical development program for oral GLP-1 receptor agonist PF-07081532. Pfizer investor and corporate communications.

  2. Pfizer Inc. (2023). Pfizer announces topline results from Phase 2 study of danuglipron and updates oral GLP-1 development strategy. Pfizer investor and corporate communications.

  3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

  4. U.S. Food and Drug Administration. (2024). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

  5. Novo Nordisk. (2024). Wegovy, Ozempic, and Rybelsus prescribing information. Novo Nordisk.

  6. Eli Lilly and Company. (2024). Mounjaro and Zepbound prescribing information. Eli Lilly and Company.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.